Gritstone's candidate is a self-amplifying messenger RNA vaccine (samRNA), which uses a slightly different technology to the mRNA-based jabs from Pfizer/BioNTech and Moderna.

Gritstone Bio GRTS is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, ...

A phase one trial of a multivariant COVID-19 Vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester and Manchester University NHS ...

Gritstone bio manufactured the GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate). GRANITE demonstrated a favorable safety and tolerability profile.

Here are some of the highlights: Emeryville, California-based start-up Gritstone bio presented updated results from a phase 1/2 trial of GRANITE, its personalised neoantigen vaccine candidate ...

Gritstone had drawn $40 million from that credit ... In extended its reach into infectious diseases with an HIV vaccine deal with Gilead Sciences Inc., and Covid-19 after the pandemic initially ...

Nov. 11, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (OTC: GRTSQ), a clinical-stage Gritstone bio (GRTSQ) witnesses a hammer chart pattern, indicating support found by the stock after losing some ...